← All candidates
Nine insider buys in the last year — $275.6K in all.
42 filings on record.
MYOMYOMO, INC.
NYSE American · Healthcare · $51.09M
$1.29
+4.03% · Sep 16
Nine insider buys in the last year — $275.6K in all.
Nothing in the last fortnight.
Price · 1Y · daily● 9 buys● 4 sells◆ 3 8-K
▸ hover a marker for the filing · drag to zoom · daily bars sharpen to 30-min on close ranges · 4 moves explained
Reverse-split 1×. When a company does a reverse split, the chart rewrites its old prices to look far bigger than they really were — so the high early prices here aren't what MYO ever actually traded at. The drop is real, but those huge old numbers aren't.
AI brief · from the filings on this pagePro
The filings, the score and the setup on this page, read for you in about ten seconds — what the insiders did, and what stands against it.
Market cap
$51.09M
Float
27.9M
70% public
Short % float
Pro
Price / profit
—
not yet profitable
Price / future profit
—
Price / sales
1.2
The buyers
▸ each insider's past open-market buys, measured ~6 months (120 trading days) later, against the S&P over the same spans · split-adjusted · pre-scheduled 10b5-1 plan trades excluded · past outcomes, not predictions
Director
Manko Joseph M. Jr.
Bought $146.9K on May 14 — 170,830 sh @ $0.8602, held indirect, 7.5% of their stake.
No completed positions to measure
Director
Kirk Thomas F
Bought $57.5K on Aug 25 — 50,000 sh @ $1.15, held direct, 11% of their stake.
0 of 1 position beat the S&P
Chief Executive Officer
Gudonis Paul R
Bought $47.3K on Aug 15 — 50,000 sh @ $0.9459, held direct, 4.0% of their stake.
0 of 1 position beat the S&P
Institutional stakes
▸ a holder crossing 5% files Schedule 13D if they intend to act on the company, 13G if they certify they will not · /A amends an earlier filing
1 filingnewest first
The record
newest first
DateTypeInsiderOf stakeShares @ priceValue
37 more transactions on Pro →Context
Wall St
$4.42 avg target
+242.6% vs today · 5 analysts · consensus Strong Buy
▸ relayed analyst opinion, which tends to run optimistic — not our forecast or advice
Earnings · EPS vs forecast
2 of 4 quarters beat
Q1 '26−$0.09 act+$0.02
Q4 '25−$0.09 act−$0.00
Q3 '25−$0.09 act+$0.02
Q2 '25−$0.11 act−$0.00
Coverage
The file stays open
42 filings on record.
The next one will be too.
▸ SEC EDGAR · FINRA · Nasdaq — public sources only · research, not advice